vaccin
spectacularli
success
remain
import
infect
therapeut
prevent
vaccin
either
exist
insuffici
efficaci
one
exampl
infect
caus
herp
simplex
viru
recent
estim
place
worldwid
preval
current
vaccin
treat
prevent
infect
sever
new
candid
vaccin
develop
recent
year
enter
clinic
evalu
anoth
exampl
influenza
viru
infect
annual
infect
rate
influenza
viru
yearli
death
rate
worldwid
lie
accord
estim
time
vaccin
remain
season
ie
need
updatedreformul
everi
influenza
season
typic
subunit
vaccin
least
trival
compris
hemagglutinin
influenza
viru
strain
influenza
b
viru
strain
refer
tiv
recent
live
attenu
influenza
viru
vaccin
laiv
introduc
updat
systemat
review
metaanalysi
publish
document
mean
efficaci
tiv
realtim
rt
pcr
virusconfirm
influenza
age
group
limit
data
avail
adult
year
age
older
mean
efficaci
laiv
young
children
higher
littl
protect
found
adult
year
older
recent
studi
report
mean
overal
vaccin
efficaci
season
lower
efficaci
person
year
age
older
thu
current
avail
influenza
vaccin
provid
moder
protect
virolog
confirm
diseas
protect
longlast
especi
tenuou
senior
popul
ongo
research
aim
develop
vaccin
elicit
potent
antibodi
cell
respons
conserv
viral
epitop
third
exampl
concern
mycobacterium
tuberculosi
infect
affect
onethird
world
popul
yearli
death
rate
million
concern
industri
world
rise
drugresist
form
diseas
vaccin
use
live
bacillu
bcg
vaccin
whose
efficaci
appear
variabl
adult
candid
vaccin
current
develop
includ
virusvector
vaccin
present
bcg
antigen
adjuv
subunit
vaccin
wholecel
vaccin
exampl
includ
malaria
hivaid
exampl
reveal
adequ
protect
mani
import
infect
yet
avail
research
continu
new
immun
approach
appear
urgent
need
question
whether
live
attenu
vaccin
retain
capac
replic
provid
robust
protect
immun
inactiv
nonrepl
vaccin
alreadi
debat
year
ago
sever
recent
studi
attempt
address
issu
directli
one
studi
compar
immun
respons
hiv
envelop
antigen
express
attenu
replic
vector
replicationdefect
adenoviru
vector
chimpanze
model
inocul
replic
recombin
result
greater
frequenc
hiv
envelopespecif
interferon
gammasecret
peripher
blood
lymphocyt
better
prime
cell
prolif
respons
higher
antienvelop
bind
neutral
antibodi
titer
better
antibodydepend
cellular
cytotox
anoth
studi
attenu
vaccinia
viru
mvtt
express
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
mvtt
compar
replicationdefect
vaccinia
viru
mva
express
protein
mva
intranas
intraor
vaccin
mice
mvtt
produc
higher
neutral
antibodi
level
mva
yet
anoth
studi
employ
mous
ocular
challeng
model
demonstr
attenu
replic
strain
replicationdefect
strain
elicit
protect
immun
respons
find
support
theori
attenu
replic
virus
induc
complet
potent
immun
respons
autolog
heterolog
antigen
correspond
nonrepl
virus
hypothes
viru
vector
could
replic
control
fashion
nearli
effici
respect
wildtyp
viru
refer
replicationcompet
control
viru
vector
would
induc
even
potent
complet
immun
respons
express
heterolog
antigen
correspond
attenu
vector
hypothesi
part
base
ration
expect
effici
replic
viru
produc
stronger
inflammatori
respons
attenu
viru
inflammatori
respons
result
potent
activ
innat
immun
system
consequ
strong
last
b
cell
respons
realiz
immun
strategi
regul
system
must
employ
reliabl
stringent
control
viral
replic
capabl
turn
howev
viru
dissemin
administr
simpli
restrict
number
replic
cycl
enough
depend
number
cycl
allow
less
pronounc
manifest
toxic
typic
viral
vector
use
henc
regul
system
must
capabl
exert
region
control
viral
replic
immun
viru
replic
local
certain
caus
diseas
phenotyp
facilit
construct
replicationcompet
control
viru
vector
advantag
may
taken
gene
switch
develop
previous
eukaryot
cell
choic
impli
backbon
viru
must
select
group
virus
doublestrand
dna
genom
eg
herpesvirus
produc
doublestrand
dna
intermedi
replic
util
host
machineri
transcript
appear
abovedescrib
requir
best
met
promot
certain
heat
shock
protein
hsp
gene
stringent
control
revers
heatactiv
endogen
transcript
factor
viru
one
prefer
two
replicationessenti
gene
place
control
promot
could
activ
undergo
one
round
local
replic
administr
mild
heat
dose
inocul
region
round
may
induc
repeat
heat
treatment
howev
viru
replic
may
ineffici
heat
activ
hsp
promot
rapidli
revers
may
unsaf
unintend
weak
activ
could
trigger
high
fever
intox
etc
inocul
subject
previous
describ
twocompon
hsp
promoterbas
gene
switch
lack
unwant
properti
fig
first
compon
compris
gene
smallmolecul
regul
smr
activ
transactiv
ta
ta
gene
control
promot
cassett
contain
promot
tarespons
promot
trp
second
compon
trp
drive
select
viral
gene
vg
heat
treatment
prompt
express
ta
inact
unless
activ
smr
activ
ta
mediat
express
viral
gene
autoactiv
express
gene
switch
inactiv
withdraw
smr
present
applic
virusmedi
lysi
host
cell
present
report
present
first
studi
immun
respons
induc
replicationcompet
control
vector
one
two
replicationessenti
gene
subject
regul
heat
smrdepend
gene
switch
articl
submit
onlin
preprint
archiv
twocompon
hsp
promoterbas
gene
switch
employ
vector
present
studi
reli
transactiv
activ
narrow
class
antiprogestin
includ
mifepriston
uliprist
chimer
protein
consist
dnabind
domain
saccharomyc
cerevisia
transcript
factor
truncat
ligandbind
domain
human
progesteron
receptor
transcript
activ
domain
human
protein
dna
segment
contain
promot
cassett
consist
human
promot
sitecontain
promot
function
link
gene
insert
gene
wildtyp
strain
intermedi
vector
util
construct
vector
vector
replicationessenti
immediateearli
ie
gene
earli
gene
place
gene
switch
control
replac
resid
promot
latter
intermedi
vector
promot
fig
vector
replicationessenti
late
gene
subject
gene
switch
control
replac
promot
promot
replic
previous
shown
strictli
depend
activ
heat
antiprogestin
singlestep
growth
experi
activ
recombin
replic
nearli
effici
wildtyp
viru
administ
footpad
mice
replic
subsequ
activ
treatment
local
administ
heat
presenc
system
antiprogestin
result
singlestep
growth
experi
shown
fig
recombin
replic
approxim
well
follow
heat
treatment
presenc
antiprogestin
uliprist
replic
observ
either
heat
antiprogestin
treatment
absenc
treatment
verifi
replic
also
tightli
control
vivo
two
three
group
mice
administ
viru
pfu
per
mous
footpad
mice
one
group
given
uliprist
intraperiton
p
h
later
subject
heat
treatment
footpad
min
one
day
later
mice
euthan
dna
rna
extract
feet
analyz
quantit
pcr
qpcr
rtqpcr
respect
substanti
larger
amount
dna
detect
feet
heatulipristaltr
mice
untreat
mice
fig
express
sever
viral
gene
observ
activ
viru
unactiv
viru
strongli
suggest
viral
replic
gene
express
occur
subsequ
heatuliprist
activ
induct
protect
immun
evalu
mous
footpad
lethal
challeng
model
first
experi
viru
vector
replicationincompet
recombin
administ
anesthesia
plantar
surfac
rear
feet
adult
swiss
webster
outbr
femal
mice
pfu
per
anim
anim
per
group
concurr
h
later
anim
one
group
receiv
intraperiton
inject
mgkg
bodi
weight
mifepriston
three
hour
inocul
mice
group
subject
heat
treatment
min
immers
hind
feet
temperaturecontrol
water
bath
twentytwo
day
later
anim
challeng
lethal
dose
wildtyp
strain
administ
rout
origin
viru
inoculum
surviv
anim
follow
lethal
endpoint
reach
ie
surviv
anim
fulli
recov
fig
induc
modest
level
immun
expect
replic
also
express
major
transcript
regul
unactiv
provid
compar
degre
protect
activ
produc
far
greater
protect
effect
therefor
one
round
effici
replic
andor
express
master
regul
result
express
viral
protein
produc
dramat
enhanc
protect
immun
note
heat
antiprogestin
treatment
systemat
effect
level
protect
induc
replicationdefect
viru
see
statist
evalu
data
compar
experi
determin
whether
immun
activ
reduc
replic
challeng
viru
effect
unactiv
replicationdefect
viru
addit
group
anim
anim
per
group
immun
challeng
wildtyp
viru
describ
four
day
challeng
anim
euthan
feet
dissect
homogen
viru
present
homogen
titrat
rabbit
skin
rs
cell
result
reveal
activ
reduc
challeng
viru
replic
nearli
order
magnitud
pfu
unactiv
recombin
viru
pfu
pfu
order
magnitud
versu
mock
infect
pfu
next
examin
similar
experi
whether
induct
enhanc
protect
immun
caus
activ
heat
antiprogestindepend
gene
switch
control
express
recombin
subsequ
experi
uliprist
util
instead
mifepriston
former
compound
activ
gene
switch
coactiv
latter
compound
furthermor
heat
treatment
regimen
chang
heat
exposur
min
achiev
greater
reproduc
experi
result
reveal
enhanc
protect
achiev
follow
activ
heat
treatment
presenc
uliprist
fig
heat
treatment
alon
uliprist
alon
significantli
increas
protect
effect
produc
unactiv
viru
find
strongli
suggest
activ
dualrespons
gene
switch
prompt
express
regul
replicationessenti
gene
well
effici
viru
replic
turn
result
observ
enhanc
protect
respons
note
experi
viru
inoculum
pfu
rather
pfu
experi
tabl
fig
see
fig
may
account
somewhat
elev
level
protect
induc
unactiv
greatli
enhanc
protect
respons
result
transient
activ
gene
switch
anim
could
due
effici
viru
replic
trigger
activ
andor
activ
gene
major
transcript
regul
turn
stimul
express
viral
gene
primarili
infect
cell
anoth
question
relat
whether
abund
viral
gene
express
secondarili
infect
cell
may
includ
antigenpres
cell
could
enhanc
immun
respons
sinc
gene
regul
littl
express
viral
gene
expect
occur
absenc
anoth
activ
treatment
recombin
late
gene
subject
regul
construct
examin
issu
compar
mous
footpad
challeng
model
result
reveal
activ
provid
similar
level
protect
fig
absenc
activ
protect
effect
either
recombin
modest
take
data
experi
account
averag
protect
effect
unactiv
unactiv
see
statist
evalu
data
compar
experi
fact
two
recombin
lack
express
differ
protein
absenc
activ
induc
compar
modest
protect
respons
strongli
suggest
absenc
one
viral
protein
limit
immun
respons
recombin
instead
vigor
replic
activ
recombin
enhanc
protect
respons
secondarili
infect
cell
activ
expect
express
viral
protein
except
regul
capsid
protein
approxim
normal
level
contrast
lack
express
absenc
activ
exhibit
dramat
curtail
express
viral
protein
find
induc
compar
protect
respons
suggest
viral
protein
express
secondarili
infect
cell
contribut
relev
fashion
immun
respons
howev
exclud
possibl
immun
system
suffici
sensit
detect
low
level
viral
antigen
express
occur
cell
secondarili
infect
next
investig
whether
second
activ
treatment
appli
day
first
treatment
ie
time
initi
round
replic
complet
second
immun
would
enhanc
protect
wildtyp
viru
challeng
second
immun
administ
week
initi
viru
applic
booster
viru
either
activ
left
unactiv
shown
fig
group
mice
immun
pfuanim
recombin
activ
viru
induc
immun
respons
protect
anim
challeng
wildtyp
viru
second
immun
similar
dose
anim
protect
howev
occur
booster
viru
also
subject
activ
treatment
second
activ
singl
dose
appar
effect
effect
reimmun
may
appar
mice
immun
smaller
quantiti
viru
experi
also
featur
parallel
group
anim
immun
boost
pfuanim
recombin
fig
document
second
immun
follow
viru
activ
even
pronounc
effect
viru
dose
note
part
experi
second
activ
appear
modestli
enhanc
protect
immun
respons
statist
signific
relev
data
immunizationchalleng
experi
conduct
use
essenti
ident
protocol
assembl
tabl
result
metaanalysi
data
present
graphic
fig
differ
immun
efficaci
activ
unactiv
found
highli
signific
also
signific
increas
protect
afford
second
immun
activ
vector
effect
second
activ
day
viru
administr
first
activ
statist
relev
presenc
level
antibodi
capabl
neutral
strain
assess
sera
mice
treat
activ
unactiv
hsvg
vector
replicationincompet
viru
pfu
per
anim
week
earlier
expect
neutral
antibodi
could
detect
subsequ
immun
unactiv
hsvg
fig
antibodi
level
sera
unactiv
hsvg
vectorimmun
anim
compar
activ
induc
neutral
antibodi
respons
clearli
superior
induc
unactiv
assess
cellular
immun
respons
respond
cell
present
peripher
blood
mononuclear
cell
pbmc
mice
immun
week
earlier
quantifi
modifi
limit
dilut
lymphoprolifer
assay
unactiv
hsvg
vector
viru
found
capabl
induc
detect
level
respond
cell
fig
substanti
better
respons
produc
activ
evalu
immun
respons
heterolog
antigen
express
hsvg
vector
recombin
construct
recombin
deriv
insert
intergen
region
express
cassett
compris
gene
equin
influenza
viru
eiv
hemagglutinin
ha
eiv
ha
function
link
cytomegaloviru
cmv
immediateearli
promot
fig
express
influenza
viru
gene
verifi
group
adult
femal
balbc
mice
inocul
rear
footpad
either
salin
pfu
per
anim
group
well
one
group
subject
activ
treatment
anoth
group
underw
activ
treatment
twice
second
treatment
administ
day
first
treatment
one
day
last
treatment
anim
euthan
rna
extract
one
hind
foot
protein
result
rtqpcr
analysi
ha
gene
express
shown
fig
result
eiv
haspecif
enzymelink
immunosorb
assay
elisa
fig
ha
rna
ha
could
detect
sampl
anim
abundantli
anim
subject
activ
treatment
ha
rna
protein
level
appear
somewhat
higher
twiceactiv
anim
onceactiv
anim
assess
immun
respons
addit
group
mice
inocul
salin
mock
immun
pfu
three
group
anim
group
two
group
subject
activ
treatment
anim
one
group
receiv
second
activ
treatment
day
later
anim
sacrif
day
postimmun
serum
sampl
test
abil
neutral
eiv
expect
neutral
antibodi
detect
unimmun
shown
mockimmun
vectorimmun
anim
fig
unactiv
capabl
induc
modest
neutral
antibodi
respons
activ
shortli
inocul
result
severalfoldmagnifi
respons
note
twiceactiv
elicit
respons
margin
better
elicit
onceactiv
viru
statist
signific
haspecif
respond
cell
present
pbmc
quantifi
type
respond
cell
frequenc
rcf
assay
use
assess
number
respond
cell
haspecif
respond
cell
detect
unimmun
shown
mockimmun
fig
anim
induct
cellular
immun
respons
observ
anim
immun
subject
activ
treatment
activ
vector
produc
similar
respons
far
greater
number
haspecif
respond
cell
found
anim
immun
twiceactiv
onceactiv
replicationcompet
control
recombin
induc
consider
potent
protect
immun
respons
replicationdefect
strain
twiceimmun
anim
complet
protect
lethal
challeng
level
partial
protect
engend
unactiv
unactiv
lack
express
differ
viral
protein
compar
strongli
suggest
muchenhanc
protect
provid
activ
hsvg
recombin
consequ
abil
effici
replic
better
neutral
antibodi
better
cellular
immun
respons
induc
activ
hsvg
vector
indic
replic
vector
boost
cellular
immun
broadli
enhanc
immun
respons
gener
find
appear
replicationcompet
control
vector
promis
new
agent
may
better
protect
diseas
caus
virus
deriv
replicationincompetentinactiv
vaccin
possibl
also
live
attenu
vaccin
perhap
even
import
observ
suggest
replicationcompet
control
vector
excel
immun
platform
may
exploit
elabor
new
vaccin
express
influenza
viru
antigen
induc
far
potent
neutral
antibodi
antigenspecif
respond
cell
respons
antigen
express
context
vector
replic
absenc
vector
replic
extent
comparison
valid
neutral
antibodi
respons
well
antigenspecif
respond
cell
respons
influenza
viru
antigen
elicit
activ
stronger
correspond
respons
vector
antigen
second
activ
treatment
administ
day
initi
activ
replicationcompet
control
vector
consist
enhanc
protect
immun
respons
challeng
wildtyp
viru
vector
deriv
also
humor
cellular
immun
respons
influenza
viru
antigen
express
replicationcompet
control
vector
margin
enhanc
second
activ
treatment
time
determin
whether
second
activ
margin
effect
immun
system
alreadi
maxim
engag
initi
immun
optim
condit
second
activ
treatment
identifi
immun
replicationcompet
control
vector
repres
novel
paradigm
may
elabor
variou
way
therefor
work
present
regard
first
illustr
principl
gener
number
dna
virus
includ
member
herpesviru
subfamili
may
employ
construct
replicationcompet
control
vector
select
fulli
virul
strain
backbon
gs
vector
sever
reason
includ
fact
hsv
doublestrand
dna
genom
integr
host
genom
toler
sizeabl
insert
support
stabl
express
heterolog
gene
replic
lyse
cell
effici
respond
antivir
drug
although
hsv
endem
human
popul
avail
data
indic
preexist
immun
obstacl
vaccinationimmun
use
hsv
vector
discuss
refer
furthermor
latent
infect
consid
manag
issu
replic
replicationcompet
control
vector
stringent
control
reactiv
capabl
occur
absenc
activ
regard
twocompon
hsp
promoterbas
gene
switch
use
control
viral
replic
sever
liganddepend
transactiv
known
may
consid
incorpor
gene
switch
includ
transactiv
deriv
bacteri
tetracyclin
repressor
bacteri
repressor
well
chimer
transactiv
exploit
ligandbind
domain
variou
steroid
receptor
eg
human
progesteron
human
estrogen
insect
ecdyson
receptor
activ
dimer
previous
construct
analyz
twocompon
hsp
promoterbas
gene
switch
coactiv
antiprogestin
ecdysteroid
ponasteron
rapamycinrapalog
regul
hsvg
vector
made
use
heat
antiprogestinactiv
gene
switch
strictli
depend
heat
antiprogestin
thoroughli
character
gene
switch
also
recommend
sever
reason
compris
transactiv
activ
narrow
spectrum
antiprogestin
progestin
sinc
includ
truncat
ligandbind
domain
progesteron
receptor
suscept
ligandindepend
activ
fact
mani
year
experiment
use
antiprogestinindepend
activ
report
low
dose
activ
antiprogestin
mifepriston
uliprist
expect
neg
effect
immun
system
antiprogestin
also
safeti
test
human
subject
readili
avail
consid
essenti
activ
ingredi
primari
use
emerg
contracept
maintain
maxim
safeti
human
immun
scenario
ie
preclud
possibl
reactiv
latenc
antiprogestin
administ
subsequ
immun
hsvgstype
vector
therefor
vector
may
employ
immun
healthi
femal
subject
reproduct
age
younger
subject
may
forego
later
use
antiprogestin
emerg
contracept
contrast
hsvg
vector
may
well
suit
immun
agent
platform
middleag
elderli
subject
note
may
feasibl
disabl
replic
fulli
activ
hsvg
vector
latent
infect
cell
engin
replicationcompet
control
viru
vector
may
capabl
make
uniqu
contribut
immun
immunocompromis
patient
estim
adult
popul
unit
state
unit
kingdom
immunocompromis
patient
particularli
vulner
vaccineprevent
diseas
would
greatli
benefit
effect
vaccin
owe
condit
immun
respons
inactiv
subunit
vaccin
may
inadequ
unfortun
use
live
attenu
vaccin
might
produc
balanc
persist
immun
respons
problemat
perceiv
danger
vaccin
may
insuffici
control
weaken
immun
system
may
caus
diseas
intend
prevent
accord
relev
guidelin
live
attenu
vaccin
contraind
patient
immunosuppress
therapi
hiv
patient
low
count
henc
use
current
market
vaccin
tuberculosi
bcg
measl
mump
rubella
varicellazost
viru
rotaviru
influenza
viru
nasal
yellow
fever
viru
univers
discourag
newer
effect
vaccin
develop
eg
new
pertussi
vaccin
also
may
becom
avail
immunocompromis
replicationcompet
control
viru
vector
express
antigen
microb
context
effici
viral
replic
expect
elicit
immun
reaction
similar
potent
contraind
live
attenu
vaccin
escap
immun
control
issu
replic
vector
activ
safe
deactiv
independ
immun
statu
patient
report
focus
immun
effect
onceactiv
replicationcompet
control
vector
undergo
one
round
replic
note
viral
vector
intend
limit
one
cycl
replic
advanc
potenti
vaccin
socal
disabl
infecti
singlecycl
disc
virus
typic
gene
glycoprotein
h
critic
infect
delet
compar
disc
virus
replicationcompet
control
virus
latter
replic
nearli
effici
wildtyp
viru
use
construct
compar
inform
avail
disc
virus
advanc
vaccin
candid
replic
disc
virus
local
occur
throughout
host
depend
dose
viru
administ
singl
round
replic
dissemin
viru
expect
result
signific
toxic
surprisingli
intracrani
administr
disc
viru
tahsv
result
neurotox
order
magnitud
lower
wildtyp
viru
strain
deriv
replicationcompet
control
virus
devoid
toxic
virtual
incap
replic
unless
deliber
activ
note
stringenc
replic
block
could
increas
subject
addit
replicationessenti
gene
gene
switch
control
furthermor
even
though
progeni
viru
produc
disc
viru
upon
immun
suppos
capabl
reinfect
cell
latent
infect
observ
latent
infect
known
involv
spread
cell
cell
henc
point
disc
virus
tahsv
appear
leaki
replic
vivo
abovement
properti
disc
virus
desir
immun
agent
vector
administ
healthi
peopl
would
disqualifi
virus
use
person
impair
immun
system
clinic
trial
conduct
investig
disc
viru
therapeut
vaccin
recurr
genit
herp
result
neg
disc
viru
tahsv
studi
deriv
minim
virul
wildtyp
strain
moreov
viru
administ
rel
low
dose
appar
avoid
toxic
failur
trial
surpris
unlik
convent
vaccin
replicationcompet
control
vector
requir
activ
administr
subject
immun
activ
need
neither
costli
inconveni
singl
uliprist
dose
administ
oral
time
immun
regard
heat
treatment
develop
small
pad
conduct
heat
inocul
region
crystal
supercool
salt
solut
pad
capabl
maintain
temperatur
min
heat
dose
shown
suffici
strong
activ
promot
promot
use
twocompon
gene
switch
control
hsvg
vector
layer
skin
human
subject
rs
cell
gift
e
wagner
propag
minim
essenti
medium
eagl
salt
mem
life
technologiesthermo
fisher
scientif
supplement
heatinactiv
calf
serum
atlanta
biolog
lawrencevil
ga
mgml
lglutamin
uml
penicillin
streptomycin
life
technolog
vero
cell
procur
american
type
cultur
collect
atcc
vero
cellderiv
cell
obtain
n
deluca
propag
dulbecco
modifi
eagl
medium
dmem
heatinactiv
fetal
calf
serum
uml
penicillin
streptomycin
strain
delet
strain
obtain
j
steven
stock
propag
cell
medium
supplement
nm
mifepriston
infect
cultur
subject
daili
heat
treatment
min
three
success
day
eiv
gift
lengsfeld
propag
madindarbi
canin
kidney
mdck
cell
atcc
dmem
supplement
heatinactiv
hors
serum
previous
describ
stock
eiv
titrat
use
tissu
cultur
infect
dose
assay
mdck
cell
cell
cultur
mifepriston
obtain
sigmaaldrich
uliprist
acet
dinnov
pharmaceut
inc
chengdu
sichuan
peopl
republ
china
compound
usp
grade
virus
construct
use
wildtyp
strain
backbon
viral
recombin
gener
homolog
recombin
engin
plasmid
along
purifi
virion
dna
rs
cell
transfect
calcium
phosphat
precipit
method
previous
describ
plasmid
use
engin
insert
transactiv
cassett
promot
compris
sequenc
clone
strain
fig
construct
previous
describ
deriv
intermedi
vector
contain
insert
gene
transactiv
cassett
contain
gene
control
promot
cassett
combin
human
promot
promot
place
gene
regul
promot
plasmid
pbsk
construct
plasmid
contain
promot
insert
recombin
arm
plasmid
pbsk
promot
compris
six
copi
yeast
upstream
activ
sequenc
ua
adenoviru
tata
sequenc
synthet
intron
excis
plasmid
invitrogen
life
technolog
aatii
hindiii
result
fragment
gel
purifi
vector
pbsk
digest
aatii
hindiii
result
fragment
gel
purifi
treat
shrimp
alkalin
phosphatas
ligat
last
two
fragment
place
promot
front
transcript
start
site
produc
recombin
rs
cell
cotransfect
plasmid
pbsk
purifi
virion
dna
subsequ
addit
mifepriston
medium
cotransfect
cell
expos
min
incub
subsequ
day
cell
incub
min
return
pick
amplif
plaqu
screen
plaqu
purif
perform
essenti
describ
result
plaquepurifi
verifi
southern
blot
well
pcr
dna
sequenc
analysi
recombin
junction
plasmid
pbsk
construct
delet
region
promot
ie
synthes
two
pcr
fragment
one
bp
bp
either
side
delet
clone
pb
ks
deriv
vector
contain
insert
gene
gene
cassett
express
eiv
ha
gene
driven
cmv
ie
promot
recombin
plasmid
construct
follow
sequenti
step
first
fragment
contain
region
span
intergen
region
nucleotid
nt
plasmid
subclon
pb
multipleclon
site
mc
remov
digest
kpnisaci
yield
pb
cassett
contain
synthet
cmv
ie
promot
flank
pbssk
mc
ligat
pb
digest
cut
gene
yield
plasmid
pin
eiv
ha
gene
pcr
clone
cdna
prepar
eiv
briefli
rna
prepar
trizol
extract
stock
eiv
pragu
revers
transcrib
use
omniscript
revers
transcriptas
qiagen
accord
manufactur
instruct
cdna
clone
pb
clone
contain
ha
gene
confirm
sequenc
analysi
ha
gene
subclon
plasmid
insert
behind
cmv
promot
plasmid
pin
yield
plasmid
produc
recombin
rs
cell
cotransfect
plasmid
purifi
virion
dna
subsequ
addit
mifepriston
medium
cotransfect
cell
expos
min
incub
subsequ
day
cell
incub
min
return
pick
amplif
plaqu
screen
plaqu
purif
perform
essenti
describ
result
plaquepurifi
verifi
southern
blot
well
pcr
dna
sequenc
analysi
recombin
junction
plasmid
construct
pcr
clone
promot
code
sequenc
gene
pb
ks
use
strain
virion
dna
pcr
target
confluent
monolay
vero
cell
infect
multipl
infect
moi
viru
allow
adsorb
h
inoculum
remov
cell
overlaid
complet
medium
uliprist
treatment
nm
initi
time
initi
infect
heat
treatment
perform
either
immedi
infect
h
later
float
seal
dish
water
bath
min
dish
incub
h
h
postinfect
two
dish
remov
cell
scrape
medium
harvest
subject
two
freezethaw
cycl
infecti
viru
determin
titrat
lysat
dish
triplic
plate
confluent
cell
transfect
h
prior
infect
express
vector
use
lipofectamin
life
technolog
plaqu
visual
day
infect
use
antibodi
plaqu
assay
essenti
previous
describ
briefli
femal
outbr
swiss
webster
mice
envigo
tampa
fl
balbc
mice
envigo
tampa
fl
experi
involv
inocul
appropri
viral
vector
phosphatebuff
salin
pb
ph
lightli
abrad
plantar
surfac
rear
feet
previous
describ
facilit
effici
uptak
vector
minim
amount
abras
requir
feet
salin
treat
prior
infect
follow
procedur
employ
mice
first
anesthet
isofluran
inhal
flunixin
meglumin
mgkg
administ
intramuscularli
im
allevi
pain
associ
procedur
thereaft
steril
salin
inject
subepiderm
rear
footpad
mice
return
cage
four
hour
later
mice
anesthet
im
inject
cocktail
acepromazin
mgkg
xylazin
mgkg
ketamin
mgkg
rear
footpad
anesthet
mice
lightli
abrad
emeri
board
scratch
keratin
layer
skin
allow
viru
adsorb
effici
anesthet
mice
rest
back
appropri
dilut
viral
vector
place
footpad
use
pipett
viral
vector
allow
adsorb
mice
awok
activ
vector
replic
combin
heat
mifepristoneuliprist
treatment
use
heat
treatment
perform
immers
hind
limb
temperaturecontrol
water
bath
h
viru
administr
mice
allow
recov
min
mifepriston
mgkg
uliprist
dimethyl
sulfoxid
dmso
administ
intraperiton
ip
time
immun
h
later
immun
control
mice
challeng
infect
rear
footpad
pfu
typic
strain
procedur
salin
pretreat
anesthesia
applic
viru
describ
applic
viral
vector
except
mifepristoneuliprist
heat
treatment
administ
efficaci
determin
modifi
endpoint
analysi
use
mice
monitor
daili
cage
code
mask
fashion
mice
reach
clinic
endpoint
indic
sever
central
nervou
system
cn
infect
bilater
hind
limb
paralysi
inabl
move
touch
trembl
euthan
serum
neutral
studi
blood
collect
retroorbit
bleed
prior
immun
retroorbit
bleed
mice
anesthet
ketamin
mgkg
xylazin
mgkg
ip
collect
serum
lymphocyt
week
immun
mice
group
anesthet
inhal
isofluran
total
blood
volum
mous
collect
mice
euthan
cervic
disloc
pbmc
isol
ficol
gradient
separ
use
lymphoprep
miltenyi
biotec
bergisch
gladbach
germani
accord
manufactur
protocol
collect
blood
allow
clot
min
centrifug
g
serum
collect
serum
sampl
heat
h
inactiv
complement
dilut
complet
dmem
contain
heatinactiv
fetal
bovin
serum
fb
neutral
suspens
contain
approxim
pfu
strain
ad
dilut
serum
final
volum
eiv
neutral
suspens
contain
approxim
unit
eiv
ad
dilut
serum
final
volum
initi
serum
dilut
therefor
serumviru
mixtur
place
rocker
room
temperatur
h
amount
viru
neutral
given
concentr
serum
titrat
rs
mdck
eiv
cell
monolay
order
calcul
neutral
antibodi
titer
eivspecif
respond
cell
quantifi
modifi
limit
dilut
lymphoprolifer
assay
use
either
cellfre
eiv
ha
protein
lysat
control
antigen
lysat
briefli
well
plate
coat
antigen
extract
rs
cell
control
lysat
eiv
ha
vero
cell
control
lysat
allow
air
dri
laminar
flow
hood
dilut
mous
pbmc
dmem
ad
well
well
contain
minimum
maximum
lymphocyt
per
well
volum
complet
medium
serum
plate
incub
h
medium
contain
thymidin
ad
plate
h
medium
replac
plate
incub
addit
h
well
harvest
dna
precipit
volum
cold
trichloroacet
acid
transfer
onto
glass
fiber
disc
whatman
gfc
filtrat
rins
ethanol
dri
use
heat
lamp
filter
transfer
scintil
vial
scintivers
fisher
scientif
count
count
per
minut
cpm
thymidin
convert
rcf
use
maximumlikelihood
estim
method
levin
et
al
group
n
femal
outbr
swiss
webster
mice
anesthet
inocul
hsvg
vector
rear
footpad
describ
uliprist
administ
ip
time
infect
three
hour
viru
administr
heat
treatment
perform
immers
rear
feet
water
bath
min
mice
allow
recov
min
mice
sacrif
h
heat
induct
feet
dissect
snapfrozen
rnalat
sigmaaldrich
dna
rna
extract
grind
tissu
trizol
thermo
fisher
scientif
back
extract
dna
interfac
extract
dna
subject
taqman
realtim
pcr
qpcr
quantit
analysi
dna
use
dna
polymeras
primersprob
rna
analyz
revers
transcript
taqman
realtim
pcr
rtqpcr
presenc
thymidin
kinas
tk
capsid
protein
glycoprotein
c
gc
transcript
normal
dna
rna
quantiti
rel
adenin
phosphoribosyltransferas
aprt
cellular
gene
sequenc
primer
probe
use
provid
tabl
order
produc
antigen
elisa
insert
plasmid
describ
subclon
express
vector
millipor
protein
express
escherichia
coli
accord
manufactur
instruct
induct
growth
bacteria
lyse
protein
isol
presenc
proteas
inhibitor
protein
use
coat
elisa
plate
allow
air
dri
dilut
murin
serum
appli
well
plate
incub
room
temperatur
min
serum
remov
well
wash
time
pb
horseradish
peroxidaseconjug
antiigg
antibodi
ad
well
plate
incub
min
room
temperatur
well
wash
time
pb
ad
well
plate
incub
min
read
spectrophotomet
plate
reader
result
evalu
base
sampl
meannegativecontrol
mean
sn
ratio
data
set
analyz
use
twoway
analysi
varianc
anova
repeat
measur
rm
unless
otherwis
state
figur
legend
data
present
mean
valu
standard
deviat
kaplanmei
surviv
curv
analyz
signific
use
log
rank
test
data
set
analyz
statist
signific
vari
sampl
size
anim
studi
approv
univers
florida
institut
anim
care
use
committe
iacuc
perform
accord
approv
protocol
protocol
experi
carri
adher
guid
care
use
laboratori
anim
nation
institut
health
american
veterinari
medic
associ
guidelin
euthanasia
